HCC Diagnostic Test
Hepatocellular carcinoma
Clinical POCActive
Key Facts
About Senseera
AI‑powered cfChIP‑seq liquid biopsy delivering cell‑state biomarkers from a simple blood draw.
View full company profileTherapeutic Areas
Other Hepatocellular carcinoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Namodenoson (CF102) | Can Fite Biopharma | Phase IIb/III |
| DCR-MYC | Dicerna Pharmaceuticals | Preclinical |
| RYZ801 | RayzeBio | Preclinical |
| CT011 | CARsgen Therapeutics | Phase II |
| BRVT101 | Biorevert | Preclinical |
| BRVT121 | Biorevert | Phase I |
| BRVT151 | Biorevert | Phase I |
| RG6139 (RO7247669) | Chugai Pharmaceutical | Phase III |
| ALN-BCAT | Alnylam Pharmaceuticals | Phase 1 |
| HCC Program | Arcellx | Discovery |
| TTFields | Novocure | Pilot |
| RP2 | Replimune | Phase 2 |